Physician
Anesthesia Services Associates PLLC
Anesthesia Services Associates PLLC was paid $2.97M by Medicaid between Jan 2018 and Aug 2018, across 92 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
33Billing provider infoANESTHESIA SERVICES ASSOCIATES PLLC
HENDERSONVILLE, TN 37075
HENDERSONVILLE, TN 37075
33aNPI1104854124assigned 06/29/2006
33bProvider typeAnesthesiology Physician
28Total paid$2.97M
24GClaims125,567
24DCodes billed92
24AFirst – last monthJan 2018 – Aug 2018
Compared with peers
Next to other Anesthesiology Physician providers in Tennessee
Rank by total paid#3 of 64
Median peer was paid$14K
This provider vs. median207×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 125,567 | $2.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 40,931 | 30,268 | $1.05M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 26,966 | 22,146 | $424K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 11% | 12,400 | 9,592 | $340K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 8.1% | 3,337 | 2,554 | $241K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 7.5% | 3,725 | 3,022 | $222K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 5.4% | 2,099 | 909 | $161K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.7% | 2,016 | 1,511 | $79K |
| 62323 | 2.4% | 754 | 498 | $71K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 1,092 | 740 | $54K |
| 64493 | 1.6% | 970 | 576 | $47K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 865 | 660 | $29K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 195 | 149 | $26K |
80 more codes
| 64494 | <1% | 811 | $19K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,606 | $15K |
| 99408 | <1% | 1,342 | $12K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 946 | $11K |
| 99406 | <1% | 3,183 | $11K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 3,699 | $10K |
| 64483 | <1% | 113 | $10K | |
| 64495 | <1% | 291 | $8K | |
| 64484 | <1% | 106 | $7K | |
| 64635 | <1% | 43 | $7K | |
| 80346 | <1% | 574 | $6K | |
| 62321 | <1% | 39 | $6K | |
| 96103 | <1% | 1,637 | $6K | |
| 27096 | <1% | 21 | $6K | |
| 95911 | <1% | 69 | $5K | |
| 80362 | <1% | 562 | $5K | |
| 80348 | <1% | 725 | $5K | |
| 80354 | <1% | 730 | $5K | |
| 80372 | <1% | 696 | $5K | |
| 80373 | <1% | 696 | $5K | |
| 95886 | <1% | 116 | $4K | |
| 80361 | <1% | 376 | $4K | |
| 64450 | <1% | 50 | $4K | |
| 80356 | <1% | 422 | $4K | |
| 99152 | <1% | 139 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 132 | $2K |
| 82670 | <1% | 131 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 126 | $2K |
| 80363 | <1% | 126 | $2K | |
| 84403 | <1% | 131 | $2K | |
| 84270 | <1% | 131 | $2K | |
| 82627 | <1% | 130 | $2K | |
| 83992 | <1% | 126 | $2K | |
| 84144 | <1% | 131 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 646 | $1K |
| 80369 | <1% | 277 | $1K | |
| 80336 | <1% | 240 | $1K | |
| 80365 | <1% | 162 | $1K | |
| 80323 | <1% | 117 | $1K | |
| 80375 | <1% | 126 | $1K | |
| 82533 | <1% | 131 | $1K | |
| 80353 | <1% | 127 | $1K | |
| 80358 | <1% | 126 | $1K | |
| 80359 | <1% | 126 | $1K | |
| 80324 | <1% | 126 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 195 | $1K |
| 82607 | <1% | 132 | $1K | |
| 64636 | <1% | 24 | $992.24 | |
| 80061 | Lipid panel | <1% | 123 | $963.64 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 99 | $960.66 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 142 | $957.71 |
| 84480 | <1% | 131 | $936.16 | |
| 83735 | <1% | 210 | $835.61 | |
| 83525 | <1% | 131 | $733.87 | |
| 76942 | <1% | 57 | $699.45 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 129 | $660.54 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 631 | $627.40 |
| 84439 | <1% | 131 | $553.86 | |
| 80338 | <1% | 120 | $496.91 | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 322 | $490.36 |
| 62370 | <1% | 44 | $484.97 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 242 | $482.96 |
| 99153 | Mod sedat endo service >5yrs | <1% | 112 | $450.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,682 | $414.20 |
| 80366 | <1% | 135 | $379.88 | |
| 80355 | <1% | 135 | $345.12 | |
| 80357 | <1% | 118 | $331.15 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 127 | $330.64 |
| 80360 | <1% | 118 | $257.38 | |
| 80367 | <1% | 103 | $229.86 | |
| 80368 | <1% | 120 | $229.60 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 362 | $217.73 |
| 82962 | <1% | 128 | $182.59 | |
| 81025 | <1% | 39 | $155.48 | |
| 80329 | <1% | 118 | $115.90 | |
| 83721 | <1% | 123 | $86.75 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 115 | $59.29 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 185 | $14.77 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 257 | $12.13 |
| 82040 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDICKERSON, STEVEN (PRESIDENT)
Parent organizationANESTHESIA SERVICES ASSOCIATES, PLLC